LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: COVID-19 Testing.

    Brooks, Zoe C / Das, Saswati

    American journal of clinical pathology

    2020  Volume 154, Issue 5, Page(s) 575–584

    Abstract: Objectives: To illustrate how patient risk and clinical costs are driven by false-positive and false-negative results.: Methods: Molecular, antigen, and antibody testing are the mainstay to identify infected patients and fight the severe acute ... ...

    Abstract Objectives: To illustrate how patient risk and clinical costs are driven by false-positive and false-negative results.
    Methods: Molecular, antigen, and antibody testing are the mainstay to identify infected patients and fight the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To evaluate the test methods, sensitivity (percent positive agreement [PPA]) and specificity (percent negative agreement [PNA]) are the most common metrics utilized, followed by the positive and negative predictive value-the probability that a positive or negative test result represents a true positive or negative patient. The number, probability, and cost of false results are driven by combinations of prevalence, PPA, and PNA of the individual test selected by the laboratory.
    Results: Molecular and antigen tests that detect the presence of the virus are relevant in the acute phase only. Serologic assays detect antibodies to SARS-CoV-2 in the recovering and recovered phase. Each testing methodology has its advantages and disadvantages.
    Conclusions: We demonstrate the value of reporting probability of false-positive results, probability of false-negative results, and costs to patients and health care. These risk metrics can be calculated from the risk drivers of PPA and PNA combined with estimates of prevalence, cost, and Reff number (people infected by 1 positive SARS-CoV-2 carrier).
    MeSH term(s) Betacoronavirus/pathogenicity ; COVID-19 ; COVID-19 Testing ; Clinical Laboratory Techniques/methods ; Coronavirus Infections/diagnosis ; False Negative Reactions ; Humans ; Pandemics ; Pneumonia, Viral/diagnosis ; Risk ; SARS-CoV-2 ; Sensitivity and Specificity
    Keywords covid19
    Language English
    Publishing date 2020-10-10
    Publishing country England
    Document type Journal Article
    ZDB-ID 2944-0
    ISSN 1943-7722 ; 0002-9173
    ISSN (online) 1943-7722
    ISSN 0002-9173
    DOI 10.1093/ajcp/aqaa141
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: COVID-19 Testing

    Brooks, Zoe C / Das, Saswati

    Am J Clin Pathol

    Abstract: OBJECTIVES: To illustrate how patient risk and clinical costs are driven by false-positive and false-negative results. METHODS: Molecular, antigen, and antibody testing are the mainstay to identify infected patients and fight the severe acute respiratory ...

    Abstract OBJECTIVES: To illustrate how patient risk and clinical costs are driven by false-positive and false-negative results. METHODS: Molecular, antigen, and antibody testing are the mainstay to identify infected patients and fight the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To evaluate the test methods, sensitivity (percent positive agreement [PPA]) and specificity (percent negative agreement [PNA]) are the most common metrics utilized, followed by the positive and negative predictive value-the probability that a positive or negative test result represents a true positive or negative patient. The number, probability, and cost of false results are driven by combinations of prevalence, PPA, and PNA of the individual test selected by the laboratory. RESULTS: Molecular and antigen tests that detect the presence of the virus are relevant in the acute phase only. Serologic assays detect antibodies to SARS-CoV-2 in the recovering and recovered phase. Each testing methodology has its advantages and disadvantages. CONCLUSIONS: We demonstrate the value of reporting probability of false-positive results, probability of false-negative results, and costs to patients and health care. These risk metrics can be calculated from the risk drivers of PPA and PNA combined with estimates of prevalence, cost, and Reff number (people infected by 1 positive SARS-CoV-2 carrier).
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #766514
    Database COVID19

    Kategorien

  3. Article ; Online: COVID-19 Testing

    Brooks, Zoe C / Das, Saswati

    American Journal of Clinical Pathology

    2020  Volume 154, Issue 5, Page(s) 575–584

    Abstract: Abstract Objectives To illustrate how patient risk and clinical costs are driven by false-positive and false-negative results. Methods Molecular, antigen, and antibody testing are the mainstay to identify infected patients and fight the severe acute ... ...

    Abstract Abstract Objectives To illustrate how patient risk and clinical costs are driven by false-positive and false-negative results. Methods Molecular, antigen, and antibody testing are the mainstay to identify infected patients and fight the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To evaluate the test methods, sensitivity (percent positive agreement [PPA]) and specificity (percent negative agreement [PNA]) are the most common metrics utilized, followed by the positive and negative predictive value—the probability that a positive or negative test result represents a true positive or negative patient. The number, probability, and cost of false results are driven by combinations of prevalence, PPA, and PNA of the individual test selected by the laboratory. Results Molecular and antigen tests that detect the presence of the virus are relevant in the acute phase only. Serologic assays detect antibodies to SARS-CoV-2 in the recovering and recovered phase. Each testing methodology has its advantages and disadvantages. Conclusions We demonstrate the value of reporting probability of false-positive results, probability of false-negative results, and costs to patients and health care. These risk metrics can be calculated from the risk drivers of PPA and PNA combined with estimates of prevalence, cost, and Reff number (people infected by 1 positive SARS-CoV-2 carrier).
    Keywords General Medicine ; covid19
    Language English
    Publisher Oxford University Press (OUP)
    Publishing country uk
    Document type Article ; Online
    ZDB-ID 2944-0
    ISSN 1943-7722 ; 0002-9173
    ISSN (online) 1943-7722
    ISSN 0002-9173
    DOI 10.1093/ajcp/aqaa141
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top